Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical InternationalZJYL -3.80%66 Return-on-Tangible-Equity is -0.75% as of Mar. 2026. GuruFocus rates ZJYL with a GF Score™ of 66/100 and a GF Value™ of $12.85 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 756 Medical Devices & Instruments companies, Jin Medical International ranks worse than 51.06% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Jin Medical International's annualized net income for the quarter that ended in Mar. 2026 was $-0.22 Mil. Jin Medical International's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $28.87 Mil. Therefore, Jin Medical International's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -0.75%.
The historical rank and industry rank for Jin Medical International's Return-on-Tangible-Equity or its related term are showing as below:
ZJYL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.16 Med: 16.76 Max: 21.52
Current: 4.16
During the past 6 years, Jin Medical International's highest Return-on-Tangible-Equity was 21.52%. The lowest was 4.16%. And the median was 16.76%.
ZJYL's Return-on-Tangible-Equity is ranked worse than 51.06% of 756
companies
in the Medical Devices & Instruments industry
Industry Median: 4.965
vs ZJYL: 4.16
Jin Medical International (NAS:ZJYL) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jin Medical International Return-on-Tangible-Equity Related Terms
Jin Medical International Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Jin Medical International's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jin Medical International Return-on-Tangible-Equity Chart
ZJYL vs RGNT, BNGO, RVP: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Jin Medical International's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jin Medical International's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -0.75% mean?
Jin Medical International (ZJYL) has a Return-on-Tangible-Equity of -0.75% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jin Medical International and its competitors. Over the past decade, Jin Medical International's Return-on-Tangible-Equity has ranged from 4.16 to 21.52. According to the industry distribution chart, Jin Medical International ranks #386 out of 756 companies in the Medical Devices & Instruments industry, placing it in the top 51.1%.
Is Jin Medical International's Return-on-Tangible-Equity too high?
Jin Medical International's current Return-on-Tangible-Equity is -0.75%. Over the past 10 years, this metric has ranged from a low of 4.16 to a high of 21.52. Based on the distribution chart, Jin Medical International ranks #386 out of 756 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Jin Medical International has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's Return-on-Tangible-Equity compare to RGNT and BNGO?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #386 out of 756 companies for Return-on-Tangible-Equity. This places Jin Medical International in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.97. Historically, Jin Medical International's own Return-on-Tangible-Equity has ranged from 4.16 to 21.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.97, based on 756 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jin Medical International and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current Return-on-Tangible-Equity is -0.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.85, compared to a current price of $2.36 — trading 81.6% below its estimated fair value. The current Return-on-Tangible-Equity is -0.75%. Jin Medical International's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current Return-on-Tangible-Equity is -0.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $2.36 is trading 81.6% below its estimated GF Value™ of $12.85.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
Return-on-Tangible-Equity: -0.75%
GF Value™: $12.85 vs. price of $2.36 (81.6% below fair value)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
66GF Score
Get the complete analysis for ZJYL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
